Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Solitary bone plasmacytoma molecular profiling and risk stratification proposes 2 categories: 1=favorable IFM score, no KRAS or TP53 MUT (PFS at 5 yrs 79%); 2=intermediate/high risk IFM + KRAS or TP53 MUT (PFS at 5 yrs 36%).”
Title: Molecular profiling and risk stratification in solitary bone plasmacytoma
Authors: Barbara Burroni, Stéphanie Harel, Raphaele Seror, Sophia Ascione, Youlia Kirova, Diane Damotte, Rakiba Belkhir, Thierry Lazure, Véronique Meignin, Justine Decroocq, Virginie Audard, Rudy Birsen, Lise Willems, Frédérique Larousserie, Patricia Franchi, Yoan Velut, Nicolas Chapuis, Laure Derrier, Salomon Manier, Bénédicte Deau-Fischer, Julien Henry, Luka Pavageau, Alexis Talbot, Bruno Royer, Didier Bouscary, Bertrand Arnulf, Jill Corre, Marguerite Vignon
You can read the Full Article in Leukemia.
You can find more posts featuring Robert Orlowski on OncoDaily.
